30 Years of PBM Evolution: The Good, The Bad, The Revolutionary

A view of a graph designs and circles.

From unexpected mergers to the onslaught of specialty drugs, the pharmaceutical industry has changed drastically over the last several decades. Is it for the better? Where is it heading?

Here, we interview industry expert, Mike Krause, who, with over 25 years of experience in the pharmaceutical sector has established himself as a leader in pharmaceutical manufacturing, managed care, and pharmacy benefits management.

Is there anything that’s happened in the industry that you didn’t expect? For example, a big shift in the market or changes that altered the industry as a whole?

There is quite a bit I didn’t expect, actually. What immediately comes to mind is the relatively unpredictable path this industry continually takes as it relates to mergers and acquisitions. A good example is the 2012 Express Scripts/Medco merger. Up until the time that Medco lost both United Health Care and CalPERS as clients, I don’t think many would have predicted that the industry’s largest rivals would become one.

The same can be said with respect to the mega-mergers we’ve now seen between carriers and PBMs. Ten years ago, very few would have predicted that Cigna would have acquired Express Scripts or CVS Health would have bought Aetna.

Also interesting is how Anthem has gone full circle from selling off NextRx, Wellpoint’s PBM in 2009, only to introduce their own PBM once again by way of IngenioRx entering the market this year.

What would you say has changed the most from the time you started to now?

Anyone who’s been in the business for a while will tell you that specialty drugs have completely reshaped the industry and the pharma supply chain. The days of a 60% generic dispensing rate and blockbuster primary care drugs like Crestor and Lipitor driving PBM and pharma profits are long gone. We’ve now transitioned to treating specialty and rare diseases where smaller patient and prescriber populations are almost entirely the focus.

PBMs, of course, have heavily invested in specialty pharmacies to capitalize on this shift. Instead of mandatory mail driving PBM profits, it’s mandatory specialty programs driving profits – at least when PBMs are in a position to mandate such a program.

Specialty drug rebate dollars, largely driven by the practice of drug exclusions, is another avenue that PBMs are driving tremendous revenue. With an average price of more than $5,000 per month and many specialty drugs with annual costs exceeding six figures, this class of drugs is fast approaching fifty percent of total pharmacy spend. Despite the warnings plan sponsors were given regarding the impending “specialty wave” many were still caught off guard, particularly smaller self-funded clients whose health care budget was thrown off by just a few unexpected specialty claims.

How has the consulting community evolved? For example, has the working relationship between consultants and PBMs improved? Or stayed the same?

I think that very few industry experts will argue against the premise that decades of little to no federal regulation has caused tremendous misalignment between payers and PBMs. That being said, the art of identifying and carefully navigating the ever-increasing number of self-serving PBM business practices has launched an entire consulting industry subset.

Today, pharmacy consultants are expected to incorporate a financial monitoring component in addition to the many services they provide. Whether this service is outsourced to an entity behind the scenes or if performed by a consultant’s internal staff, the “trust but verify” approach to ensuring a PBM is meeting contractual discount and rebate guarantees has evolved into what’s largely viewed as being a core capability of any consultant.

Additionally, an increasing number of consultants are attempting to evaluate the cost of a PBM’s formulary net of rebates and are paying attention to whether a PBM is supporting access to inefficient or wasteful products.

Manufacturers of “rebate chasing” products like Duexis and Vimovo that arguably provide little or no value when compared to non-combination lower-cost generics are finding it increasingly difficult to secure formulary coverage.

What are your thoughts on the many new players that have entered the PBM Market?

It’s great for the industry. When you consider that roughly 75% of prescriptions are filled through either Express Scripts, CVS Health, or OptumRx – market competition is extremely healthy.

The fact that new market entrants are drawing additional attention to the lack of transparency and, more importantly, in many instances these entities are substantially reducing costs, only further reinforces the premise that bigger isn’t always better in the world of PBMs.

What is the best thing that’s happened to the market?

I feel that what smart, ,automated analytics is doing to move the needle towards large cost savings is one of the best things that’s happened in recent years. The ability for any payor, consultant, or PBM to perform daily, autonomous data analyses for hundreds of clients, in coordination with electronic alerts going out to the appropriate stakeholders, is significantly lowering costs and ,impacting health outcomes.

Gone are the days of sifting through endless reports in an effort to find the three of five things that a plan sponsor can do immediately to make an impact. Waiting three or twelve months to address problems and discuss opportunities outlined in quarterly or annual reviews is far from efficient and no longer makes sense.

The Worst?

Possibly the worst thing that’s happened to the market is the ever-increasing difference between a brand drug’s list price and the actual cost realized by a payor after rebates. This is concerning for patients because a drug’s cost at the pharmacy counter is usually calculated prior to the application of rebates.

Consider the individual who has not yet reached her combined pharmacy and medical deductible who is paying the full cost at the counter – or those whose copayments are calculated as a percentage of the drug’s pre-rebate cost. In both cases, the patient pays more because of inflated list prices designed to accommodate multiple stakeholders’ appetite for rebates.

Another perverse incentive, as it relates to high list prices and rebates, can be found in what we’ve seen play out in the Part D world. For years, Part D plans have benefited from pre-rebate/high list prices by pushing beneficiaries into the catastrophic phase sooner, at which point a federal reinsurance subsidy kicks in and substantially lowers a plan’s liability. CMS is attempting to address this situation through a voluntary 5-year effort that began in 2020 called the “Part D Payment Modernization Model.” Unfortunately, 5 years is a long time to continue as usual while costs keep rising.

How is the progression of technology altering the PBM market?

Technology available through organizations, like ,Xevant, continues to reshape our industry. Cost-effective, near real-time engagement with physicians, pharmacists, and consumers is empowering payors with the ability to influence member behavior and reduce costs in new ways.

When combined with daily, automated monitoring of contractual guarantees, both PBMs and payors are realizing efficiencies and cost savings that historically required tremendous resources to achieve. As I mentioned earlier, the same can be said for efficiencies around managing the multiple PBM relationships required of consulting practices and TPAs.

Established connectivity and wide-spread adoption of Xevant’s and others’ technology allows for unprecedented automation and efficiencies related to virtually every business process impacting PBM oversight and analytics in general, including financial monitoring, reporting, and RFP analysis, to name just a few.

What are some tools that you’ve adopted (as a consumer)?

It’s hard not to acknowledge the value consumers can realize through the likes of prescription discount cards such as GoodRx and BlinkHealth. Like so many people, I’ve saved a decent chunk of change through their use. However, consumers should also understand that the sheer number of pharmacy discount cards on the market – and the profits that these entities often realize – are the result of a system with lots of room for improvement.

Much like inflated list prices perpetuate our supply chain’s need for rebates, pharmacy “usual and customary” prices enable discount card suppliers to realize a very healthy profit. It’s also important to recognize that PBMs don’t participate in discount card networks for free – they also see profits from fees for participating in these programs.

What are your thoughts on the future of the industry? Where is it going?

It’s been disappointing to see that despite intense public criticism and many attempts at federal legislation to improve the way PBMs and big Pharma interact, cost continue to escalate.

I’m optimistic that progress will be made as we continue to see transparency legislation at the state level improve. I’m also encouraged by the increased market share being secured by the small and mid-tier PBMs, as well as the sheer number of new PBMs entering the market. Also inspiring is the number of options available to payors and plan sponsors as it relates to carving out the many aspects of pharmacy benefit administration to various best-in-class entities, including those specializing in claims processing, analytics, clinical oversight, and rebate contracting. It’s hard to argue that doing so removes at least a portion of the many inherent conflicts of interest when these services are bundled with a single entity.

About Mike

Mike Krause is a healthcare sales leader with over 25 years of experience in the pharmaceutical manufacturer, managed care, and PBM industries. He currently oversees sales for Xevant, an automated PBM analytics and performance optimization platform currently used by leading consultants, health plans, and PBMs throughout the country.

Prior to Xevant, he held the position of Senior Market VP, Health Plan Sales at Navitus Health Solutions where he worked for over eight years. Mike’s tenured passion to create long-lasting, aligned partnerships has delivered tremendous value for TPAs, health plans, large purchasing groups, and fortune 500 organizations throughout the country.

UNLOCK THE POWER OF ANALYTICS

views

Try Xevant for Free

Sign Up for Blog Updates

Name
This field is for validation purposes and should be left unchanged.

Search Blog

Xevant

Xevant logo with stylized X.

Blog Sign up

Subscribe to our blog and receive the latest Xevant news and updates.

Name
This field is for validation purposes and should be left unchanged.

Ashwin Patel

SVP, Data

Ashwin (Ash) has more than 20 years leadership experience in data warehousing and business intelligence practices within the healthcare sector. At Xevant, Ash leads the data and business intelligence teams and is responsible for future state expansion of Xevant data technology platforms and processes, partnering with the organization’s product teams to develop best-in-class products and solutions. Prior to Xevant, Ash was VP Business Intelligence for HealthSmart Benefit Solutions based in Irving, TX, a third-party administrator (TPA) of medical, pharmacy, and clinical data. Ash earned a Bachelor of Science degree in computer science and operations research from Leeds Becketts University in Leeds, England.

Sahily Paoline

Chief Pharmacy Officer

Sahily is a licensed pharmacist and expert business leader with more than 20 years of experience delivering high-quality clinical care, building and leading organizations, and staffing and motivating teams in the pharmaceutical and digital health industries. Sahily specializes in Clinical Program Management, Pharmacy Practice and Operations, and building and growing business. She is passionate about the use of data and technology in patient care and believes in a holistic approach to healthcare.

Megan Foster

Manager, People Operations

Todd Rode

VP, Revenue Operations

Todd served as an Artillery officer in the U.S. Army before a disability turned his focus to the business world. He’s carried a bag, led multiple sales operations and sales development efforts, and run a sales team in complex selling environments. The son of small business owners, Todd enjoys helping business leaders grow by using proven, repeatable processes. He holds a BS from the United States Military Academy at West Point and an MBA from the Kellogg School of Management at Northwestern University. Todd lives in Nashville with his wife. He spends as much time outside as possible and co-founded a brewery in 2019.  He’d love to tell you the full story over a pint sometime.

Marvin Roi Elvambuena

Software Development Manager

Marvin is responsible for all aspects of software development efforts at Xevant, including architecting and managing software solutions from the ground up. He brings with him a performance history of leading loosely defined enterprise software projects in rapid changing environments. He has previously worked in several industries such as HR solutions, insurance, shared services, and payroll and holds a BS in Information Technology with specialization in Web Development.

Greg Abram

VP Sales

Greg is a results-driven sales professional with more than 12 years of experience in the PBM and healthcare markets. As VP of Sales, Greg leads the Xevant sales team focused on growing revenue and expanding market reach. Prior to Xevant, Greg served in multiple leadership and growth positions with Myriad Genetics, Navitus Health Solutions, Catamaran, and CVS Caremark Corporation. Greg’s passion to create long-lasting, aligned partnerships has delivered tremendous value for PBMs, health plans, large purchasing groups, and fortune 500 organizations throughout the country.

Jaylyn Palmer

Chief of Staff

Jaylyn is a dynamic Chief of Staff who thrives on helping create workplaces that go beyond the ordinary to achieve a culture of belonging, empowerment, and improvement. Proving to be a culture ambassador, strategic advisor, and relationship builder, Jaylyn supports the organization with versatility and innovation. When she’s not wearing one of her many Xevant hats, you can find Jaylyn planning a party, attending live music and theater, or playing Dungeons and Dragons.

Jeff Weber

Chief People Officer

Jeff has extensive experience building and growing positive organizational culture that supports high performance, transparency, learning and growth. Jeff has implemented comprehensive talent strategy including talent acquisition, engagement, rewards, and recognition programs. Prior to Xevant, Jeff was the EVP People and Places at Instructure, a rapidly growing provider of the Canvas and Bridge learning management platforms focused on transforming online learning and employee development.Jeff also led the growth of the people function for Ancestry.com. Jeff holds an MBA with an emphasis in Organizational Behavior from Brigham Young University.

Scott Sorenson

Chief Technology Officer

Scott is an expert business leader with extensive experience scaling technology organizations. His experience includes technology leadership roles at Cedar Health Payment Solutions, Human Longevity, Inc., and 16 years at Ancestry where he was the Chief Technology Officer and played an integral role scaling the Ancestry family history business that hosts billions of historical records and serves millions of customers. He also led their technology organization as they transformed the business to include a world class consumer genomics product line. At Ancestry, Scott prepared the technology organization for an IPO and multiple PE transactions.

Daniel Telford

Director, Corporate Treasurer

Daniel is a financial professional with more than 15 years of financial and management experience. Having worked in multiple demanding roles including Business Banker, Licensed Investment Professional and Financial Center Manager, Daniel uses his experience to guide and inform his current role as Corporate Treasurer for Xevant. Daniel has led multiple complex cross-functional teams to sustained success in the financial services industry.

Griff McGee

Corporate Controller

Griffin is CPA and finance and accounting professional with more than 10 years’ experience in public accounting, internal audit, and consulting. Throughout his career Griffin has worked with clients to solve complex problems, improve and implement new processes and achieve public company readiness. Prior to joining Xevant, Griffin served in several audit and consulting roles with Protiviti, Change Healthcare, Genesco and Decosimo, CPAs.
Xevant logo with stylized X.

Download our new ebook

The New PBM Playbook

EBOOK TOPICS
  • Technology as the Catalyst
  • Data, Data, and More Data
  • Embrace Automation
  • The Power of Acting Now

Gerrit Lemmen

VP, Rebates

Gerrit is an experienced leader in the PBM, Specialty and Formulary rebate markets. As VP of Rebates at Xevant, Gerrit is responsible for managing drug rebates through Xevant’s revolutionary pharmacy benefits platform. In his previous roles at Magellan Rx Management, Gerrit led highly respected commercial rebate operations teams and focused on increasing efficiency that enabled scalability and growth.

Mike Simmons

VP, Product Management

Mike is a true product champion & ambassador with 18+ years of experience in critical product launch, strategic branding, and delivering profitable campaigns that capture market share and create growth. His vision and skills for implementing integrated, high-impact, go-to-market strategies have proven to drive increased sales and an overall improvement of marketing programs. Mike’s ability to leverage business savvy in order to align management, data intelligence, and content management generate more informed business decisions resulting in enhanced revenue for progressive, enterprise organizations.

Laura Phillipson

VP, Client Experience

Laura Phillipson is a client management expert with experience managing client services teams. Her past roles include Sr. Client Services Executive for Navitus and over a decade of experience as a Certified Pharmacy Technician. Laura’s career in client relations spans nearly two decades. An avid sports fan, Laura excels in helping clients create a strong strategy with a competitive edge. Laura’s extensive background in both customer service and the medical field provides an ideal blend to lead client management for Xevant.

Chad Davis

Director, Compliance

Chad is a credentialed and strategic audit and compliance professional with more than 10 years’ experience assisting companies with achieving their business objectives through adept governance, compliance, and risk management. Prior to Xevant, Chad served in several auditing and accountant roles for Protiviti, Intermountain Healthcare, and First Data Corporation. He is a credentialed CISM and CISA and holds a BS in Accounting.

Erin Glenn

Director, Data Warehouse

Erin is 20-year data warehousing and business intelligence technology leader who has conceptualized, designed, and implemented ground-breaking data-centric technology solutions. She has solved big problems, delivered operational efficiencies, and increased productivity and cost savings throughout her career by delivering enterprise class data warehouses and business intelligence solutions.  Prior to Xevant, Erin served in multiple technology leadership positions with Hampton Roads Transit, MSN, The Port of Virginia, and Innova Systems. She holds a bachelor’s degree from the University of Hawaii.

Greg Heaps

Chief Marketing Officer

Greg is an expert marketer and innovative business builder specializing in launching and building high growth companies. As a founding member and on the leadership team of multiple venture backed tech startups, Greg has extensive experience in numerous markets including software services, health and medicine, commercial real estate, and consumer focused products. His primary motivation is driving demand and growth through an omni channel, go-to-market strategy. When Greg is not neck deep building an exhilarating business, he can often be found mountain biking, fly fishing, or carving deep powder on remote mountains.

Headshot of Jace Garfield, the Chief Technology Officer.

Jace Garfield

Chief Analytics Officer

Jason (Jace) Garfield, MSW has thrived in many industries ranging from data and information technology to foster care and mental health management. In his role with the Utah State Justice Commission, he helped publish medical research on drug effectiveness. Jason’s passion for technology and data automation paved the way towards innovations in identifying new to market drugs, tracking systems to identify clinical interventions, and data automations, resulting in millions in operational cost reductions. At Xevant, Jace leads every aspect of product operations and is responsible for a diverse team of technology experts.

Jason Hardin

Chief Revenue Officer

With 20+ years of sales and sales management experience in SaaS sales and professional services, Jason is a dynamic, performance driven leader with an exceptional record of achievement in motivating sales teams to exceed quotas, while ensuring client success.  Having led many organizations in the start-up, high growth, and emerging phases, Jason brings an entrepreneurial hunger to the sales, client success, and business development organizations with the ability to penetrate new markets, produce high growth sales results, achieve adoption and retention goals, and grow market share and revenue quickly.  

Jeff Lininger

President & COO

Jeff is the Chief Operating Officer at Xevant and is accountable for operational excellence at the company. Prior to joining Xevant, Jeff successfully applied his extensive, multidisciplinary expertise in building and scaling growth and service infrastructures within start-up, mid-market, and Fortune 500 technology and services companies. He has recruited and built new leadership and functional teams within operations, sales, marketing, product development, client success, finance, and HR. The success of these business transformations also contributed to a culture of increased accountability and empowerment, contributing to significant improvement in employee engagement and overall enhanced business performance. Jeff holds an MBA from Duke University’s Fuqua School of Business in North Carolina and a Bachelor’s Degree in Finance and Economics from Grove City College in Pennsylvania.

Headshot of Lindsay Jones, the Chief Financial Officer.

Lindsay Jones

Chief Financial Officer

Lindsay Jones, CPA, is a financial executive with experience in start-up companies & mature enterprises. He has a proven track record of helping, leading, and enhancing executive management teams. He has worked with private equity groups and private investors to identify, analyze, and close acquisitions and divestitures of companies. He has founded two startup companies, owned his own business, and closed over $500 million in private and public equity and debt financing, in his twenty-year career. 

Brandon Newman

Chief Executive Officer

Brandon has a dynamic, 25-year leadership career spearheading several businesses with emphasis on growth, revenue, and sales performance. He has run many high-growth environments, including start-ups, turnarounds, and $1B+ dollar businesses. As a serial entrepreneur, he has a proven record of founding new businesses and advancing them through growth and acquisition, merger, or roll-up including ScripPoint, Veridian, and AviaraMD. He is the driving force for vision, new market strategy, revenue growth, technology development, and partner alliances.